Liver fibrosis has evolved from a laboratory discipline to a clinically relevant condition for hepatologists. Advances in understanding its molecular mechanisms, natural history, and detection methods have shown that cirrhosis can be reversible, and effective antifibrotic therapies may significantly alter liver disease management. Clinicians now view fibrosis as a distinct clinical problem amenable to specific diagnostic and therapeutic approaches, independent of etiology. This review integrates current knowledge of fibrosis in various chronic liver diseases with recent advances in its pathophysiology, emphasizing recent developments. Cirrhosis is the end stage of fibrosis, characterized by nodule formation and altered liver function. It is now recognized that cirrhosis can be reversible, and fibrosis is a consequence of sustained wound healing in chronic liver injury. The clinical manifestations of cirrhosis vary widely, and up to 40% of patients are asymptomatic. Cirrhosis is prevalent in the US, with 360 per 100,000 population, and is a leading cause of death among hepatobiliary diseases. The molecular composition of scar tissue in cirrhosis is similar regardless of etiology, consisting of extracellular matrix components, collagen types I and III, sulfated proteoglycans, and glycoproteins. Non-invasive markers for fibrosis are urgently needed due to the limitations of current methods. Serum markers, which measure molecules in blood as surrogates for fibrosis, are being developed. Current serum assays of single matrix molecules or their fragments are not liver-specific and may underestimate 'quiescent' cirrhosis. Recent efforts to assay multiple markers from the same serum sample aim to improve discrimination between fibrosis stages. Current assays measure breakdown products of extracellular matrix (ECM) constituents and enzymes involved in their production or modification. Other non-invasive markers include a clinical and laboratory index developed by Poynard, which correlates with fibrosis stage in chronic HCV. Potential future markers include imaging modalities like PET scanning, receptor imaging, and magnetic resonance (MR). Liver diseases associated with fibrosis include chronic viral hepatitis, steatohepatitis, autoimmune liver disease, and metabolic disorders. The natural history of fibrosis varies, with HCV having the most studied progression. Risk factors for rapid fibrosis progression in HCV include older age at infection, concurrent liver disease, male gender, increased BMI, and HIV infection. The ability to assess fibrosis progression rate is valuable for clinical management, as it informs treatment decisions and prognosis. There is now unequivocal evidence that cirrhosis can be reversible. This is supported by studies showing that cirrhosis can regress following the elimination of the underlying cause, such as HBV or HCV. Animal models have provided insights into the mechanisms of fibrosis reversal. Recent advances in understanding the pathophysiology of hepatic fibrosis include the role of inflammatory cells, the contribution of steatosis to fibrogenesis,Liver fibrosis has evolved from a laboratory discipline to a clinically relevant condition for hepatologists. Advances in understanding its molecular mechanisms, natural history, and detection methods have shown that cirrhosis can be reversible, and effective antifibrotic therapies may significantly alter liver disease management. Clinicians now view fibrosis as a distinct clinical problem amenable to specific diagnostic and therapeutic approaches, independent of etiology. This review integrates current knowledge of fibrosis in various chronic liver diseases with recent advances in its pathophysiology, emphasizing recent developments. Cirrhosis is the end stage of fibrosis, characterized by nodule formation and altered liver function. It is now recognized that cirrhosis can be reversible, and fibrosis is a consequence of sustained wound healing in chronic liver injury. The clinical manifestations of cirrhosis vary widely, and up to 40% of patients are asymptomatic. Cirrhosis is prevalent in the US, with 360 per 100,000 population, and is a leading cause of death among hepatobiliary diseases. The molecular composition of scar tissue in cirrhosis is similar regardless of etiology, consisting of extracellular matrix components, collagen types I and III, sulfated proteoglycans, and glycoproteins. Non-invasive markers for fibrosis are urgently needed due to the limitations of current methods. Serum markers, which measure molecules in blood as surrogates for fibrosis, are being developed. Current serum assays of single matrix molecules or their fragments are not liver-specific and may underestimate 'quiescent' cirrhosis. Recent efforts to assay multiple markers from the same serum sample aim to improve discrimination between fibrosis stages. Current assays measure breakdown products of extracellular matrix (ECM) constituents and enzymes involved in their production or modification. Other non-invasive markers include a clinical and laboratory index developed by Poynard, which correlates with fibrosis stage in chronic HCV. Potential future markers include imaging modalities like PET scanning, receptor imaging, and magnetic resonance (MR). Liver diseases associated with fibrosis include chronic viral hepatitis, steatohepatitis, autoimmune liver disease, and metabolic disorders. The natural history of fibrosis varies, with HCV having the most studied progression. Risk factors for rapid fibrosis progression in HCV include older age at infection, concurrent liver disease, male gender, increased BMI, and HIV infection. The ability to assess fibrosis progression rate is valuable for clinical management, as it informs treatment decisions and prognosis. There is now unequivocal evidence that cirrhosis can be reversible. This is supported by studies showing that cirrhosis can regress following the elimination of the underlying cause, such as HBV or HCV. Animal models have provided insights into the mechanisms of fibrosis reversal. Recent advances in understanding the pathophysiology of hepatic fibrosis include the role of inflammatory cells, the contribution of steatosis to fibrogenesis,